Terms: = Thyroid cancer AND KDR, VEGFR2, 3791, ENSG00000128052, P35968, VEGFR, CD309, FLK1
205 results:
1. Apatinib weakens proliferation, migration, invasion, and angiogenesis of thyroid cancer cells through downregulating pyruvate kinase M2.
Yang X; Li W; Han X; Wang J; Dai J; Ye X; Meng M
Sci Rep; 2024 Jan; 14(1):879. PubMed ID: 38195651
[TBL] [Abstract] [Full Text] [Related]
2. Integration of scRNA and bulk RNA-sequence to construct the 5-gene molecular prognostic model based on the heterogeneity of thyroid carcinoma endothelial cell.
Ni Z; Cong S; Li H; Liu J; Zhang Q; Wei C; Pan G; He H; Liu W; Mao A
Acta Biochim Biophys Sin (Shanghai); 2024 Feb; 56(2):255-269. PubMed ID: 38186223
[TBL] [Abstract] [Full Text] [Related]
3. The importance of early-stage blood pressure control in thyroid cancer patients treated with lenvatinib from the perspective of dose intensity.
Masaki C; Shioya J; Sugino K; Terasawa Y; Yokotsuka S; Nakata M; Kitagawa W; Ito K
Support Care Cancer; 2023 Nov; 31(12):729. PubMed ID: 38017341
[TBL] [Abstract] [Full Text] [Related]
4. Early Increases in Blood Pressure and Major Adverse Cardiovascular Events in Patients With Renal Cell Carcinoma and thyroid cancer Treated With vegfr TKIs.
Narayan V; Liu T; Song Y; Mitchell J; Sicks J; Gareen I; Sun L; Denduluri S; Fisher C; Manikowski J; Wojtowicz M; Vadakara J; Haas N; Margulies KB; Ky B
J Natl Compr Canc Netw; 2023 Oct; 21(10):1039-1049.e10. PubMed ID: 37856199
[TBL] [Abstract] [Full Text] [Related]
5. Efficacy and safety of immunotherapy combined with single-agent chemotherapy as second- or later-line therapy for metastatic non-small cell lung cancer.
Chen D; Li L; Wang M; Hu X; Jiang J; Li W; Yang L; Fan M; Shi Y; Lv F; Liu Y
Front Immunol; 2023; 14():1086479. PubMed ID: 37795095
[TBL] [Abstract] [Full Text] [Related]
6. Quinazoline-based vegfr-2 inhibitors as potential anti-angiogenic agents: A contemporary perspective of SAR and molecular docking studies.
Moradi M; Mousavi A; Emamgholipour Z; Giovannini J; Moghimi S; Peytam F; Honarmand A; Bach S; Foroumadi A
Eur J Med Chem; 2023 Nov; 259():115626. PubMed ID: 37453330
[TBL] [Abstract] [Full Text] [Related]
7. A multicenter, open-label, randomized, phase II study of cediranib with or without lenalidomide in iodine 131-refractory differentiated thyroid cancer.
Rosenberg AJ; Liao CY; Karrison T; de Souza JA; Worden FP; Libao B; Krzyzanowska MK; Hayes DN; Winquist E; Saloura V; Prescott K; Villaflor VM; Seiwert TY; Schechter RB; Stadler WM; Cohen EEW; Vokes EE
Ann Oncol; 2023 Aug; 34(8):714-722. PubMed ID: 37182801
[TBL] [Abstract] [Full Text] [Related]
8. Population Pharmacokinetics and Exposure-Response Analysis for the Phase 3 COSMIC-311 Trial of Cabozantinib for Radioiodine-Refractory Differentiated thyroid cancer.
Ly NS; Li J; Faggioni R; Roskos LK; Brose MS
Clin Pharmacokinet; 2023 Apr; 62(4):587-598. PubMed ID: 36869986
[TBL] [Abstract] [Full Text] [Related]
9. Antitumour effects of apatinib in progressive, metastatic differentiated thyroid cancer (DTC).
Shi L; You Q; Wang J; Wang H; Li S; Tian R; Yao X; Wu W; Zhang L; Wang F; Lin Y; Li S
Endocrine; 2022 Oct; 78(1):68-76. PubMed ID: 35767182
[TBL] [Abstract] [Full Text] [Related]
10. Prediction of EVT6-NTRK3-Dependent Papillary thyroid cancer Using Minor Expression Profile.
Kechin AA; Ivanov AA; Kel AE; Kalmykov AS; Oskorbin IP; Boyarskikh UA; Kharpov EA; Bakharev SY; Oskina NA; Samuilenkova OV; Vikhlyanov IV; Kushlinskii NE; Filipenko ML
Bull Exp Biol Med; 2022 Jun; 173(2):252-256. PubMed ID: 35737155
[TBL] [Abstract] [Full Text] [Related]
11. FDA Approval Summary: Cabozantinib for Differentiated thyroid cancer.
Duke ES; Barone AK; Chatterjee S; Mishra-Kalyani PS; Shen YL; Isikwei E; Zhao H; Bi Y; Liu J; Rahman NA; Wearne E; Leighton JK; Stephenson M; Ojofeitimi I; Scepura B; Nair A; Pazdur R; Beaver JA; Singh H
Clin Cancer Res; 2022 Oct; 28(19):4173-4177. PubMed ID: 35679021
[TBL] [Abstract] [Full Text] [Related]
12. The Overexpression of SLC25A13 Predicts Poor Prognosis and Is Correlated with Immune Cell Infiltration in Patients with Skin Cutaneous Melanoma.
Lv Y; Yuan CH; Han LY; Huang GR; Ju LC; Chen LH; Han HY; Zhang C; Zeng LH
Dis Markers; 2022; 2022():4091978. PubMed ID: 35607442
[TBL] [Abstract] [Full Text] [Related]
13. Effectiveness and safety of sorafenib for renal cell, hepatocellular and thyroid carcinoma: pooled analysis in patients with renal impairment.
Oya M; Kaneko S; Imai T; Tsujino T; Sunaya T; Okayama Y
Cancer Chemother Pharmacol; 2022 Jun; 89(6):761-772. PubMed ID: 35445315
[TBL] [Abstract] [Full Text] [Related]
14. CRISPR-mediated knockout of vegfr2/kdr inhibits cell growth in a squamous thyroid cancer cell line.
Tsai ML; Lee CH; Huang LC; Chen YH; Liu WN; Lin CY; Hsu KW; Lee AW; Lin CL
FEBS Open Bio; 2022 May; 12(5):993-1005. PubMed ID: 35313079
[TBL] [Abstract] [Full Text] [Related]
15. [Special tumor entities in the head and neck region : Nasopharyngeal carcinoma, salivary gland, and thyroid cancer].
Zech HB; Betz CS
HNO; 2022 Apr; 70(4):278-286. PubMed ID: 35258645
[TBL] [Abstract] [Full Text] [Related]
16. Apatinib vs Placebo in Patients With Locally Advanced or Metastatic, Radioactive Iodine-Refractory Differentiated thyroid cancer: The REALITY Randomized Clinical Trial.
Lin Y; Qin S; Li Z; Yang H; Fu W; Li S; Chen W; Gao Z; Miao W; Xu H; Zhang Q; Zhao X; Bao J; Li L; Ren Y; Lin C; Jing S; Ma Q; Liang J; Chen G; Zhang H; Zhang Y; Zhou X; Sang Y; Hou Z
JAMA Oncol; 2022 Feb; 8(2):242-250. PubMed ID: 34913959
[TBL] [Abstract] [Full Text] [Related]
17. Discovery, preclinical development, and clinical application of pralsetinib in the treatment of thyroid cancer.
Locantore P; Novizio R; Corsello A; Paragliola RM; Pontecorvi A; Corsello SM
Expert Opin Drug Discov; 2022 Feb; 17(2):101-107. PubMed ID: 34702125
[TBL] [Abstract] [Full Text] [Related]
18. Lenvatinib Plus Anti-PD-1 Combination Therapy for Advanced cancers: Defining Mechanisms of Resistance in an Inducible Transgenic Model of thyroid cancer.
Bertol BC; Bales ES; Calhoun JD; Mayberry A; Ledezma ML; Sams SB; Orlicky DJ; Donadi EA; Haugen BR; French JD
Thyroid; 2022 Feb; 32(2):153-163. PubMed ID: 34641722
[No Abstract] [Full Text] [Related]
19. Donafenib: First Approval.
Keam SJ; Duggan S
Drugs; 2021 Nov; 81(16):1915-1920. PubMed ID: 34591285
[TBL] [Abstract] [Full Text] [Related]
20. CABOCOL-01 trial: a single-arm phase II study assessing safety and efficacy of Cabozantinib for advanced or metastatic cervical carcinoma after platinum treatment failure.
Coquan E; Brachet PE; Licaj I; Leconte A; Castera M; Lequesne J; Meriaux E; Bonnet I; Lelaidier A; Clarisse B; Joly F
BMC Cancer; 2021 Sep; 21(1):1054. PubMed ID: 34563169
[TBL] [Abstract] [Full Text] [Related]
[Next]
